If you look at the pharmocokinetic studies, the bioavailability of Subcutaneous MTX gives u almost a dose response linear increase in systemic availability.

FORBES: Xeljanz, A Cheaper-But-Expensive $25,000-A-Year Pfizer Pill For Rheumatoid Arthritis, Gets FDA Green Light